Glasgow, Scotland, February 2, 2011 / b3c newswire / - Sistemic, focussed on providing microRNA-based problem solving services and kit based products to the life sciences research and development markets, is certainly living up to its high growth expectations and award winning tag as Nexxus, Most Promising Company of the Year and has now started 2011 with a bang. This month the company has signed Master Service Agreements with RedX Pharma based in Liverpool, a subsidiary of a large pharmaceutical company in Cambridge, Massachusetts and not forgetting about their home ground, Glasgow University. The gain in the market has been driven by their solid science aligned with their focused commercial strategy which in turn has driven an 82 % increase in sales from the same month a year ago. This places Sistemic on a very firm footing from which it will further expand its efforts globally over the coming year as well as marks a significant milestone in its growth.
Sistemic’s Chief Executive, Jim Reid commented that “….It has been a great start to the year and really confirms the strength and broad applicability of our technologies. Sistemic is about giving our clients more instructive information on their system from microRNA profiling, be it in drug discovery or cell QC. The Sistemic approach gives the knowledge to our clients to guide their future development or business decisions and this unique position is resulting in significant commercial interest. 2011 has started well and we expect this to continue with the company continuing to expand its patent protected portfolio of products and services, increasing its Glasgow & Boston facilities as well as expanding internationally to service its increasing global customer base”.
Dr. Neil Murray of RedX Pharma commented “We have found the Sistemic approach unique and compelling and we look forward to developing a long and mutually beneficial relationship with them where they will help us with our drug discovery programmes, to bring new treatments faster, cheaper and with more chance of success to the market”.
Sistemic’s primary business is focussed on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology markets and the Cell Therapy community. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are providing instructive information on effects on a whole cell or organism rather than an isolated pathway. This system approach means that the data produced is more indicative of the biology and more diagnostic of actual effect. Their extensive suite of tools for the Cell Therapy community includes SistemQC™ which is used to characterise cells including stem cells, as well as monitoring the QC of production. In addition, the drug development markets are served through a range of products which include SistemTOX™, SistemKB™ and SistemRNA™.
For more information please contact:
Dr. Verna McErlane
Director of Commercial Operations
Phone: + 44 (0)7855 376 358
More information about Sistemic is available at http://www.sistemic.co.uk